HNWAG
CLDX icon

High Net Worth Advisory Group’s Celldex Therapeutics CLDX Stock Holding History

High Net Worth Advisory Group’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,000
Closed -$44.6K – 259
2022
Q4 		$44.6K Hold
1,000
– – 0.02% 345
2022
Q3 		$28K Sell
1,000
-1,000
-50% -$30.7K 0.01% 410
2022
Q2 		$54K Hold
2,000
– – 0.02% 308
2022
Q1 		$68K Hold
2,000
– – 0.02% 299
2021
Q4 		$77K Buy
+2,000
New +$87.2K 0.03% 292

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

High Net Worth Advisory Group's CLDX Position: Q1 2023 in Review

High Net Worth Advisory Group sold out of Celldex Therapeutics (CLDX) in Q1 2023, closing a stake of 1,000 shares — an estimated $44.6K sold.

High Net Worth Advisory Group first reported a position in CLDX in Q4 2021 and held it in 5 quarters. The position peaked at $77K in Q4 2021. 161 funds tracked by Wall St. Rank hold CLDX as of Q1 2023.

  • High Net Worth Advisory Group reported no remaining Celldex Therapeutics position as of Q1 2023 after selling out during the quarter.
  • High Net Worth Advisory Group sold 1,000 Celldex Therapeutics shares in Q1 2023, an estimated $44.6K.
  • High Net Worth Advisory Group first reported a position in Celldex Therapeutics in Q4 2021 and held it in 5 quarters.
  • High Net Worth Advisory Group's Celldex Therapeutics position peaked at $77K in Q4 2021.
  • 161 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2023.

Based on High Net Worth Advisory Group's 13F filing for Q1 2023, filed 20 Apr 2023.